LUMiC Pedestal Cup

LUMiC_cup_gr

LUMiC Pedestal Cup

These devices are not cleared by the FDA for use in the US.

Indication:

Partial pelvic reconstruction replacement for the hip joint after many or complicated revisions or after major bone defects of the acetabulum.

System Details:

  • Cups available with and without HA coating in outer diameters of 50, 54 and 60mm
  • Fixation stems are available in cemented (Ø 8mm ) and cementless versions (Ø 8mm and Ø10 mm), each in 3 different lengths: 65, 75 and 85mm.
  • Two liner/head options:
    - The implacross® PE inserts have a 15° cranial overhang and are available in neutral version and with 4mm offset of the rotational center
    - The ACCIS® insert 15° combined with the 2M Vitamin E head offer the treatment of the hip joint with a tripolar articulation
  • Developed in collaboration with Dr. P.D.S. Dijkstra and Prof. Dr. A.H.M. Taminiau University of Leiden, The Netherlands

Coating Options Available:

  • Intelligent Silver™ (on the 60mm cup)
  • TiN

Evidence:

LUMiC in bone

LUMiC Endoprosthetic Reconstruction After Periacetabular Tumor Resection: Short-term Results

Michae¨l P. A. Bus MSc , Andrzej Szafranski MD, PhD, Simen Sellevold MD, Tomasz Goryn MD, PhD, Paul C. Jutte MD, PhD, Jos A. M. Bramer MD, PhD, M. Fiocco PhD, Arne Streitbu¨rger MD, PhD, Daniel Kotrych MD, PhD, Michiel A. J. van de Sande MD, PhD, P. D. Sander Dijkstra MD, PhD. Clin Orthop Relat Res DOI 10.1007/s11999-016-4805-4.

A retrospective assessment was conducted on every patient in whom a LUMiC prosthesis was used to reconstruct a periacetabular defect after internal hemipelvectomy for a pelvic tumor over seven years. Eight orthopaedic oncology centers had forty-seven patients with a two-year minimum follow-up (mean age of 50 years), 32 of which were still living. 90% of cases were uncemented and 62% of components used had intelligent silver coating.

  • Overall implant survival at 2 years was 91.5% and 73.5% at 5 years.
  • Adverse events included: Four recurrent dislocations—two were revised to dual mobility cups with no dislocations after. Fourteen patients experienced infection, with four necessitating implant removal. Two patients experienced aseptic loosening and were revised to cemented with no further complications.
  • Dislocation was the main mechanical complication, with adequate management from closed reduction or cup revision. Dual mobility significantly reduced dislocation risk and the authors recommend dual mobility for any internal hemipelvectomy.
  • Loosening cases were a result of poor initial fixation and the authors recommend using cemented with poor primary fixation or in-sufficient bone stock.
    • Infection remains a major risk due to length of procedure/blood loss, although most infected prostheses could be retained.
  • “Our early results are reassuring that the use of dual-mobility articulation provides for stable pelvic reconstruction in the short term.”

 

This device is not cleared by the FDA for use in the US.